Table 3 Association between lncRNA MEG3 polymorphisms and pCR rate in different comparison models
From: Association of LncRNA MEG3 polymorphisms with efficacy of neoadjuvant chemotherapy in breast cancer
SNP | Dominant model Genotypes | pCR n (%) | Non-pCR n (%) | P | Dominant model | Recessive model | Additive model | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | OR(95% CI) | P | OR(95% CI) | P | OR(95% CI) | P | |||||
rs10132552 | TT | 22(28.2) | 56(71.8) | 0.012* | 2.396(1.202~4.777) | 0.013* | 1.72(0.412~7.181) | 0.457 | TC | 2.376(1.164~4.847) | 0.017* |
|  | TC + CC | 32(48.5) | 34(51.5) |  |  |  |  |  | CC | 2.545(0.585~11.082) | 0.213 |
rs941576 | AA | 22(31.9) | 47(68.1) | 0.182 | 1.59(0.803~3.146) | 0.183 | 2.194(0.563~8.554) | 0.258 | AG | 1.479(0.731~2.994) | 0.277 |
|  | AG + GG | 32(42.7) | 43(57.3) |  |  |  |  |  | GG | 2.67(0.653~10.926) | 0.172 |
rs7158663 | GG | 28(34.1) | 54(65.9) | 0.339 | 1.393(0.705~2.75) | 0.34 | 2.959(0.678~12.916) | 0.149 | AG | 1.227(0.602~2.503) | 0.573 |
|  | AG + AA | 26(41.9) | 36(58.1) |  |  |  |  |  | AA | 3.214(0.716~14.44) | 0.128 |